Ionis Pharmaceuticals Pushes TRYNGOLZA Access as Insurer Requirements Slow Launch

Ionis Pharmaceuticals (NASDAQ:IONS) is working to accelerate prescriptions for TRYNGOLZA as physicians gain experience with the drug and patients navigate insurance requirements, CEO Brett Monia said at the Jefferies Global Healthcare Conference.

Three months into the drug’s launch for severe hypertriglyceridemia, or severely elevated triglycerides, doctors have shown enthusiasm but have initially prescribed it to relatively few patients each, Monia said. He maintained that TRYNGOLZA represents a multibillion-dollar opportunity while acknowledging that building the market will require education and easier access.

“They’ve been treating only a very small number of patients out of the gate to get familiarity with the drug, to get familiarity with the process,” Monia said.

Focus on Patients at Highest Risk

TRYNGOLZA was initially launched for familial chylomicronemia syndrome, a rare disease, before its indication was expanded to severe hypertriglyceridemia. Monia said the medicine also received European approval for severe hypertriglyceridemia the day before the conference discussion.

Monia said the company is initially focusing on nearly 1 million U.S. patients it considers at high risk of acute pancreatitis because of very high triglycerides or a previous attack. He estimated that a similar number of high-risk patients live in Europe.

Physicians are prioritizing patients who recently experienced acute pancreatitis, although prescriptions are also being written for patients without a history of the condition, Monia said. He added that the drug’s U.S. indication statement includes reductions in acute pancreatitis.

Insurance Access and Quick Start

Jefferies Head of Pharma and Biotech Research Akash Tewari asked whether insurance requirements could slow treatment even when coverage criteria appear broad. Monia said payers require patients to have tried another triglyceride-lowering drug, although that requirement is not part of TRYNGOLZA’s label.

Many high-risk patients are already taking generic treatments without adequate results, Monia said. For newly diagnosed patients, trying another treatment could take three to six months, he added.

Ionis is expanding its Quick Start program, which Monia said provides one or two months of treatment while patients move toward covered prescriptions. The company has relaxed some eligibility criteria, and early signs are encouraging, he said. Monia said the company was pleased with conversion to paid treatment after the program but did not provide a conversion figure.

Ionis is also increasing contact with physicians and using patient education campaigns to raise awareness of triglyceride levels and available treatment, Monia said.

Launch Metrics and Investor Questions

Tewari said investors wanted more information about the number of patients entering the prescription process and converting to paid treatment, particularly after a guidance cut. Monia said Ionis would continue to disclose existing launch metrics and was considering additional ones.

  • More than 1,500 prescribers had prescribed TRYNGOLZA by the end of September, three months after its severe hypertriglyceridemia approval, Monia said.
  • About 24% of prescribers had written more than one prescription by that point, a proportion Monia said was growing.
  • About 34% of commercial lives had coverage for the severe hypertriglyceridemia indication by the end of September, according to Monia.

Monia said Ionis expects coverage to expand and anticipates Medicare contracts next year. He said the company had not identified a suitable cardiovascular drug launch to use as a comparison for TRYNGOLZA’s expected trajectory.

Ionis has seven products on the market across eight indications and four medicines in phase 3 development, Monia said. Alongside TRYNGOLZA, the company is launching DAWNZERA for hereditary angioedema and ZANVASTRO for Alexander disease.

About Ionis Pharmaceuticals (NASDAQ:IONS)

Ionis Pharmaceuticals is a biotechnology company that discovers and develops RNA-targeted medicines, with a focus on antisense oligonucleotides. Its medicines are designed to act on RNA and change the production of proteins linked to disease. The company’s research and development programs span neurological, cardiovascular, metabolic and rare diseases. Ionis has developed medicines that it commercializes itself and products advanced or marketed with pharmaceutical partners. Its medicines and partnered products include treatments for conditions such as spinal muscular atrophy and transthyretin amyloidosis.